keyword
MENU ▼
Read by QxMD icon Read
search

metronomic chemotherapy

keyword
https://www.readbyqxmd.com/read/27909934/current-achievements-and-future-perspectives-of-metronomic-chemotherapy
#1
REVIEW
Adriana Romiti, Rosa Falcone, Michela Roberto, Paolo Marchetti
In recent years, many anticancer drugs have been tested at metronomic dosages for a variety of tumours. Mechanisms of action attributed to metronomic chemotherapy (MCT) include antiangiogenesis, immunomodulation, direct inhibition of tumour growth, effect on tumour initiating cells and the modulation of clonal evolution. An active clinical research, aimed at testing MCT in several cancers, has been conducted over the past 15 years. However, because the majority of available results come from earlier phase II studies, mainly performed in the area of breast cancer (BC), it is clear that there are areas still to be investigated...
December 1, 2016: Investigational New Drugs
https://www.readbyqxmd.com/read/27901449/incidence-of-sterile-hemorrhagic-cystitis-in-tumor-bearing-dogs-concurrently-treated-with-oral-metronomic-cyclophosphamide-chemotherapy-and-furosemide-55-cases-2009-2015
#2
Catherine M Chan, Angela E Frimberger, Antony S Moore
OBJECTIVE To determine the incidence of sterile hemorrhagic cystitis (SHC) in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide. DESIGN Retrospective case series. ANIMALS 55 dogs. PROCEDURES Record databases of 2 specialty practices were searched to identify dogs treated with oral metronomic cyclophosphamide chemotherapy in conjunction with furosemide for a minimum of 28 days between January 2009 and December 2015. Information extracted from the records included signalment, tumor diagnosis, cyclophosphamide and furosemide dosages, and concurrent medications...
December 15, 2016: Journal of the American Veterinary Medical Association
https://www.readbyqxmd.com/read/27881735/therapy-activated-stromal-cells-can-dictate-tumor-fate
#3
Robert S Kerbel, Yuval Shaked
In this issue of JEM, Chan et al. describe a novel way by which an investigational form of chemotherapy known as low-dose metronomic chemotherapy can inhibit tumor growth, which also has therapeutic implications for targeting tumor-initiating cells (TICs), the tumor stroma, and chemokine receptors, as well as invasion and metastasis.
November 23, 2016: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/27881732/metronomic-chemotherapy-prevents-therapy-induced-stromal-activation-and-induction-of-tumor-initiating-cells
#4
Tze-Sian Chan, Chung-Chi Hsu, Vincent C Pai, Wen-Ying Liao, Shenq-Shyang Huang, Kok-Tong Tan, Chia-Jui Yen, Shu-Ching Hsu, Wei-Yu Chen, Yan-Shen Shan, Chi-Rong Li, Michael T Lee, Kuan-Ying Jiang, Jui-Mei Chu, Gi-Shih Lien, Valerie M Weaver, Kelvin K Tsai
Although traditional chemotherapy kills a fraction of tumor cells, it also activates the stroma and can promote the growth and survival of residual cancer cells to foster tumor recurrence and metastasis. Accordingly, overcoming the host response induced by chemotherapy could substantially improve therapeutic outcome and patient survival. In this study, resistance to treatment and metastasis has been attributed to expansion of stem-like tumor-initiating cells (TICs). Molecular analysis of the tumor stroma in neoadjuvant chemotherapy-treated human desmoplastic cancers and orthotopic tumor xenografts revealed that traditional maximum-tolerated dose chemotherapy, regardless of the agents used, induces persistent STAT-1 and NF-κB activity in carcinoma-associated fibroblasts...
November 23, 2016: Journal of Experimental Medicine
https://www.readbyqxmd.com/read/27879129/on-drug-resistance-and-metronomic-chemotherapy-a-mathematical-modeling-and-optimal-control-approach
#5
Urszula Ledzewicz, Shuo Wang, Heinz Schattler, Nicolas Andre, Marie Amelie Heng, Eddy Pasquier
Effects that tumor heterogeneity and drug resistance have on the structure of chemotherapy protocols are discussed from a mathematical modeling and optimal control point of view. In the case when two compartments consisting of sensitive and resistant cells are considered, optimal protocols consist of full dose chemotherapy as long as the relative proportion of sensitive cells is high. When resistant cells become more dominant, optimal controls switch to lower dose regimens defined by so-called singular controls...
February 1, 2017: Mathematical Biosciences and Engineering: MBE
https://www.readbyqxmd.com/read/27879115/preface
#6
Avner Friedman, Mirosław Lachowicz, Urszula Ledzewicz, Monika Joanna Piotrowska, Zuzanna Szymanska
This volume was inspired by the topics presented at the international conference "Micro and Macro Systems in Life Sciences" which was held on Jun 8-12, 2015 in Będlewo, Poland. System biology is an approach which tries to understand how micro systems, at the molecular and cellular levels, affect macro systems such as organs, tissue and populations. Thus it is not surprising that a major theme of this volume evolves around cancer and its treatment. Articles on this topic include models for tumor induced angiogenesis, without and with delays, metastatic niche of the bone marrow, drug resistance and metronomic chemotherapy, and virotherapy of glioma...
February 1, 2017: Mathematical Biosciences and Engineering: MBE
https://www.readbyqxmd.com/read/27876012/phase-i-study-of-low-dose-metronomic-temozolomide-for-recurrent-malignant-gliomas
#7
Eric T Wong, Joshua Timmons, Amy Callahan, Lauren O'Loughlin, Bridget Giarusso, David C Alsop
BACKGROUND: The treatment goal for recurrent malignant gliomas centers on disease stabilization while minimizing therapy-related side effects. Metronomic dosing of cytotoxic chemotherapy has emerged as a promising option to achieve this objective. METHODS: This phase I study was performed using metronomic temozolomide (mTMZ) at 25 or 50 mg/m(2)/day continuously in 42-day cycles. Correlative studies were incorporated using arterial spin labeling MRI to assess tumor blood flow, analysis of matrix metalloproteinase-2 (MMP-2) and MMP-9 activities in the cerebrospinal fluid (CSF) as surrogates for tumor angiogenesis and invasion, as well as determination of CSF soluble interleukin-2 receptor alpha (sIL-2Rα) levels as a marker of immune modulation...
November 22, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27832971/metronomic-chemotherapy-in-head-and-neck-cancer
#8
Francesca De Felice, Ilaria Benevento, Angela Musella, Daniela Musio, Vincenzo Tombolini
Head neck cancer (HNC) is generally treated with a multimodality approach. Loco-regional-distant control is often worst, due to the advantage stage disease at diagnosis and the optimal treatment option remains an unresolved issue. Metronomic chemotherapy (MCHT) is an emerging therapeutic option in clinical oncology and it may prove useful in HNC patients.
November 8, 2016: Cancer Letters
https://www.readbyqxmd.com/read/27784377/-effect-of-cp-metronomic-chemotherapy-on-rpmi-8226-cell-proli-feration-and-notch1-nf-%C3%AE%C2%BAb-signaling-pathway-in-vitro
#9
Lie-Ping Guo, Fan Zhou, Hao-Tian Shi, Hai-Min Chen, Chen-Hui Lin, Xiao-Ling Chen, Jian Hou
OBJECTIVE: To investigate the effect of metronomic chemotherapy of low dose phosphoramide combined with prednisolone (CP metronomic chemotherapy) on proliferation and apoptosis of RPMI 8226 cells, and to explore its regulating effect on Notch1/NF-κB signaling pathways. METHODS: Experiment was divided into the DMSO control group, and the phosphoramide mustard (PM) group, the prednisolone group, the phosphoramide mustard plus prednisolone group (the CP group). RPMI 8226 cells were treated with different drugs, CCK-8 method was used to detect cell proliferation, flow cytometry was used to detect the cell cycle and apoptosis, reverse transcription PCR was used to detect Notch1 and NF-κB mRNA expression level...
October 2016: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/27775375/limiting-the-development-of-anti-cancer-drug-resistance-in-a-spatial-model-of-micrometastases
#10
Ami B Shah, Katarzyna A Rejniak, Jana L Gevertz
While chemoresistance in primary tumors is well-studied, much less is known about the influence of systemic chemotherapy on the development of drug resistance at metastatic sites. In this work, we use a hybrid spatial model of tumor response to a DNA damaging drug to study how the development of chemoresistance in micrometastases depends on the drug dosing schedule. We separately consider cell populations that harbor pre-existing resistance to the drug, and those that acquire resistance during the course of treatment...
December 1, 2016: Mathematical Biosciences and Engineering: MBE
https://www.readbyqxmd.com/read/27767434/primary-nodal-hemangiosarcoma-in-four-dogs
#11
Catherine M Chan, Courtney H Zwahlen, Louis-Philippe de Lorimier, Stephen M Yeomans, Karon L Hoffmann, Antony S Moore
CASE DESCRIPTION 4 dogs with a slow-growing mass in the cervical region were evaluated. CLINICAL FINDINGS All dogs had no clinical signs at the time of the evaluation. There was no apparent evidence of visceral metastases or other primary tumor based on available CT or MRI data for any dog. TREATMENT AND OUTCOME For each dog, surgery to remove the mass was performed. Histologic examination of the excised tissue revealed a completely excised grade 1 or 2 lymph node hemangiosarcoma. All dogs received adjuvant chemotherapy; 2 dogs underwent curative intent chemotherapy, 1 dog underwent metronomic treatment with cyclophosphamide, and 1 dog underwent metronomic treatment with chlorambucil...
November 1, 2016: Journal of the American Veterinary Medical Association
https://www.readbyqxmd.com/read/27757300/mrna-transfected-dendritic-cell-vaccine-in-combination-with-metronomic-cyclophosphamide-as-treatment-for-patients-with-advanced-malignant-melanoma
#12
Troels Holz Borch, Lotte Engell-Noerregaard, Trine Zeeberg Iversen, Eva Ellebaek, Özcan Met, Morten Hansen, Mads Hald Andersen, Per Thor Straten, Inge Marie Svane
INTRODUCTION: Vaccination with dendritic cells (DCs) has generally not fulfilled its promise in cancer immunotherapy due to ineffective translation of immune responses into clinical responses. A proposed reason for this is intrinsic immune regulatory mechanisms, such as regulatory T cells (Tregs). A metronomic regimen of cyclophosphamide (mCy) has been shown to selectively deplete Tregs. To test this in a clinical setting, we conducted a phase I trial to evaluate the feasibility and safety of vaccination with DCs transfected with mRNA in combination with mCy in patients with metastatic malignant melanoma (MM)...
2016: Oncoimmunology
https://www.readbyqxmd.com/read/27752847/metronomic-chemotherapy-with-oral-vinorelbine-mvnr-and-capecitabine-mcape-in-advanced-her2-negative-breast-cancer-patients-is-it-a-way-to-optimize-disease-control-final-results-of-the-victor-2-study
#13
M E Cazzaniga, L Cortesi, A Ferzi, L Scaltriti, F Cicchiello, M Ciccarese, S Della Torre, F Villa, M Giordano, C Verusio, M Nicolini, A R Gambaro, L Zanlorenzi, E Biraghi, L Legramandi, E Rulli
PURPOSE: The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm these results. METHODS: Patients received mVNR 40 mg three times a week and mCAPE 500 mg three times a day, continuously. The primary endpoint was the clinical benefit rate (CBR); secondary endpoints were toxicity, objective response rate (ORR), and progression-free survival (PFS)...
December 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27727857/low-dose-metronomic-chemotherapy-in-patients-of-acute-myeloid-leukemia-aml-who-are-not-eligible-for-standard-of-care-aggressive-treatment
#14
Mathur A, Singh Gp, Gurjar D, Malhotra H
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27724870/sakk-24-09-safety-and-tolerability-of-bevacizumab-plus-paclitaxel-vs-bevacizumab-plus-metronomic-cyclophosphamide-and-capecitabine-as-first-line-therapy-in-patients-with-her2-negative-advanced-stage-breast-cancer-a-multicenter-randomized-phase-iii-trial
#15
Christoph Rochlitz, Martin Bigler, Roger von Moos, Jürg Bernhard, Klazien Matter-Walstra, Andreas Wicki, Khalil Zaman, Sandro Anchisi, Marc Küng, Kyung-Jae Na, Daniela Bärtschi, Markus Borner, Tamara Rordorf, Daniel Rauch, Andreas Müller, Thomas Ruhstaller, Marcus Vetter, Andreas Trojan, Ursula Hasler-Strub, Richard Cathomas, Ralph Winterhalder
BACKGROUND: Adding bevacizumab to chemotherapy improves response rates and progression-free survival (PFS) in metastatic breast cancer (mBC). We aimed to demonstrate decreased toxicity with metronomic chemotherapy/bevacizumab compared with paclitaxel/bevacizumab. METHODS: This multicenter, randomized phase III trial compared bevacizumab with either paclitaxel (arm A) or daily oral capecitabine-cyclophosphamide (arm B) as first-line treatment in patients with HER2-negative advanced breast cancer...
October 10, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27693635/immunological-anti-angiogenic-and-clinical-effects-of-intratumoral-interleukin-12-electrogene-therapy-combined-with-metronomic-cyclophosphamide-in-dogs-with-spontaneous-cancer-a-pilot-study
#16
Laetitia Cicchelero, Sofie Denies, Katrien Vanderperren, Emmelie Stock, Leen Van Brantegem, Hilde de Rooster, Niek N Sanders
The immunological, anti-angiogenic and clinical effects of metronomic cyclophosphamide and 3 consecutive intratumoral interleukin (IL)-12 gene therapy (electrogene therapy (EGT)) treatments were evaluated in 6 dogs with spontaneous cancer. In all dogs, a decrease in peripheral leukocytes 2 days after IL-12 EGT coincided with erythema and swelling of the tumor. In the tumor, a transient increase in IL-12 levels was measured, whereas a continuous increase in interferon γ (IFNγ) and thrombospondin 1 (TSP-1) were determined in contrast to a continuous decrease in vascular endothelial growth factor (VEGF)...
September 28, 2016: Cancer Letters
https://www.readbyqxmd.com/read/27685913/metronomic-s-1-chemotherapy-plus-transcatheter-arterial-chemoembolization-tace-a-promising-treatment-of-hepatocellular-carcinoma-refractory-to-tace
#17
Wukui Huang, Lina You, Shufa Yang, Dengyao Liu, Mo Liu, Hailin Wang, Pingju Wang, Pahaerding Baikere, Peng Gu, Abulajiang Abulikemu, Shaoha Yuan, Xiwen Fan
PURPOSE: To assess the efficacy and safety of metronomic S-1 chemotherapy combination with transcatheter arterial chemoembolization (TACE) for the treatment of Barcelona Clinic Liver Cancer (BCLC) Stage B hepatocellular carcinoma (HCC) refractory to TACE. METHODS: Twenty six patients met the eligibility criteria and were enrolled. TACE was performed on day 1, and metronomic S-1 chemotherapy on days 2-15. Tumor assessment was performed one month later. The primary endpoints were time to progression (TTP) and adverse events (AE)...
July 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/27651344/high-doses-of-proton-pumps-inhibitors-in-refractory-gastro-intestinal-cancer-a-case-series-and-the-state-of-art
#18
Rosa Falcone, Michela Roberto, Chiara D'Antonio, Adriana Romiti, Annalisa Milano, Concetta Elisa Onesti, Paolo Marchetti, Stefano Fais
BACKGROUND: In recent years, proton pump inhibitors (PPIs) have been investigated at high-dose to modulate tumour microenvironment acidification thus restoring chemotherapeutic sensitivity. Moreover, several clinical data supports the role of cytotoxic drugs at low-dose continuously delivered as anticancer therapy. METHODS: Clinical records of three patients affected with gastrointestinal cancer refractory to standard treatments, who had received a combination of high-dose rabeprazole and metronomic chemotherapy were reviewed...
September 1, 2016: Digestive and Liver Disease
https://www.readbyqxmd.com/read/27647223/efficacy-and-safety-of-vinorelbine-capecitabine-oral-metronomic-combination-in-elderly-metastatic-breast-cancer-patients-victor-1-study
#19
Marina E Cazzaniga, Valter Torri, Francesca Riva, Luca Porcu, Federica Cicchiello, Serena Capici, Diego Cortinovis, Nunzio Digiacomo, Paolo Bidoli
PURPOSE: Elderly patients with metastatic breast cancer are expected to derive similar benefits from chemotherapy as younger patients, but are more likely to experience therapy-related toxicity. Data from the VICTOR-1 study showed that metronomic therapy with vinorelbine and capecitabine was effective and well tolerated in patients with metastatic breast cancer. This analysis determined the efficacy and safety of the metronomic combination of oral vinorelbine and capecitabine in a subgroup of VICTOR-1 study patients aged ≥70 years...
August 24, 2016: Tumori
https://www.readbyqxmd.com/read/27610198/highlights-from-the-1st-latin-american-meeting-on-metronomic-chemotherapy-and-drug-repositioning-in-oncology-27-28-may-2016-rosario-argentina
#20
Adriana Rosé, Nicolas André, Viviana R Rozados, Leandro E Mainetti, Mauricio Menacho Márquez, María José Rico, Paula Schaiquevich, Milena Villarroel, Lauro Gregianin, Jaume Mora Graupera, Wendy Gómez García, Sidnei Epelman, Carlos Alasino, Daniel Alonso, Guillermo Chantada, O Graciela Scharovsky
Following previous metronomic meetings in Marseille (2011), Milano (2014), and Mumbai (2016), the first Latin American metronomic meeting was held in the School of Medical Sciences, National University of Rosario, Rosario, Argentina on 27 and 28 of May, 2016. For the first time, clinicians and researchers with experience in the field of metronomics, coming from different countries in Latin America, had the opportunity of presenting and discussing their work. The talks were organised in three main sessions related to experience in the pre-clinical, and clinical (paediatric and adult) areas...
2016: Ecancermedicalscience
keyword
keyword
33012
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"